ACTA1 and nasopharyngeal carcinoma: Treating NPC with an established EMT inhibitor, the Tgf-β receptor inhibitor SB-43154254, significantly reduced α-Sma expression at 10% FBS suggesting that FBS-induced EMT may involve this pathway (Supplementary Fig. 5i)55.